Skip to main content

This website is intended exclusively for healthcare professionals residing and/or working in the KSA.

Home | go to homepage
SCIENCE
  • SCIENCE
  • Allergic Rhinitis
  • Asthma
  • Atopic Dermatitis
  • Cardiovascular
    • Cardiovascular
    • Atherothrombosis
    • Dyslipidemia
    • Thrombosis
  • Diabetes
  • Eosinophilic Esophagitis
  • Multiple Sclerosis
  • Nasal Polyps
  • Prurigo Nodularis
  • Oncology and Rare Blood Disorder
    • Oncology and Rare Blood Disorder
    • Multiple Myeloma
  • Rare Diseases
  • Vaccines
    • Vaccines
    • Influenza
    • Meningitis
    • Pertussis & Polio
    • RSV
PATIENT SUPPORT
  • PATIENT SUPPORT
  • Allergic Rhinitis
  • Atopic Dermatitis
  • Cardiovascular
  • Diabetes
    • Diabetes
    • Tools And Resources
      • Tools And Resources
      • My Dose Coach
      • Toujeo Welcome Pack
      • Soliqua Welcome Pack
      • Pre-Ramadan assessment and Risk calculation for diabetic patients during Ramadan
      • Clinical and economic value of SOLIQUA - Pharmacist perspective
  • Nasal Polyps
  • Rare Diseases
PRODUCTS
  • PRODUCTS
  • Amaryl®
  • Apidra®
  • Aprovasc®
  • Aprovel®
  • Aubagio®
  • Clexane®
  • Depakine®
  • Dupixent®
    • Dupixent®
    • Atopic Dermatitis
    • Asthma
    • Nasal Polyps
  • Lantus®
  • Plavix®
  • Praluent®
    • Praluent®
    • Praluent®
    • Praluent 300 mg
  • Sarclisa
    • Sarclisa
    • Sarclisa®
    • Sarclisa Kd®
    • Sarclisa Pd®
  • Soliqua®
    • Soliqua®
    • Soliqua®
    • SoliMix Study
    • For a Peaceful Ramadan
    • Soli-Simplify Study
  • Tavanic®
  • Toujeo®
    • Toujeo®
    • Toujeo®
    • For a Peaceful Ramadan
    • Time-in-Range
    • Real world Evidences
  • Zympass®
LOGIN
REGISTER
SEARCH
Home | go to homepage
LOGIN
REGISTER
SEARCH
Home | go to homepage
SCIENCE
  • SCIENCE
  • Allergic Rhinitis
  • Asthma
  • Atopic Dermatitis
  • Cardiovascular
    • Cardiovascular
    • Atherothrombosis
    • Dyslipidemia
    • Thrombosis
  • Diabetes
  • Eosinophilic Esophagitis
  • Multiple Sclerosis
  • Nasal Polyps
  • Prurigo Nodularis
  • Oncology and Rare Blood Disorder
    • Oncology and Rare Blood Disorder
    • Multiple Myeloma
  • Rare Diseases
  • Vaccines
    • Vaccines
    • Influenza
    • Meningitis
    • Pertussis & Polio
    • RSV
PATIENT SUPPORT
  • PATIENT SUPPORT
  • Allergic Rhinitis
  • Atopic Dermatitis
  • Cardiovascular
  • Diabetes
    • Diabetes
    • Tools And Resources
      • Tools And Resources
      • My Dose Coach
      • Toujeo Welcome Pack
      • Soliqua Welcome Pack
      • Pre-Ramadan assessment and Risk calculation for diabetic patients during Ramadan
      • Clinical and economic value of SOLIQUA - Pharmacist perspective
  • Nasal Polyps
  • Rare Diseases
PRODUCTS
  • PRODUCTS
  • Amaryl®
  • Apidra®
  • Aprovasc®
  • Aprovel®
  • Aubagio®
  • Clexane®
  • Depakine®
  • Dupixent®
    • Dupixent®
    • Atopic Dermatitis
    • Asthma
    • Nasal Polyps
  • Lantus®
  • Plavix®
  • Praluent®
    • Praluent®
    • Praluent®
    • Praluent 300 mg
  • Sarclisa
    • Sarclisa
    • Sarclisa®
    • Sarclisa Kd®
    • Sarclisa Pd®
  • Soliqua®
    • Soliqua®
    • Soliqua®
    • SoliMix Study
    • For a Peaceful Ramadan
    • Soli-Simplify Study
  • Tavanic®
  • Toujeo®
    • Toujeo®
    • Toujeo®
    • For a Peaceful Ramadan
    • Time-in-Range
    • Real world Evidences
  • Zympass®
  • LOGIN
  • REGISTER
  • SEARCH
    • Home
    • Science
    • Cutting-Edge Science

    Science at Sanofi

    Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas

    Filters

    Therapeutical Areas
    Cardiovascular
    Diabetes
    Asthma
    Atopic Dermatitis
    Nasal Polyps
    Rare diseases
    Vaccines
    Influenza
    Pertussis & Polio
    Type of Content
    Watch
    Listen
    Read

    New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin combination is very high recommended

    Post Thrombotic Syndrome in Women

    LLT and LDLC Over 2 years in CKD and ASCVD From the GOULD Registry

    Efficacy of PCSK9i on Lipid Residual Risk Lipid Real Registry

    2022 ACC Expert Consensus on ASCVD Management

    Lp(a) Levels in Global ASCVD Patients

    Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes (Solimix)

    About Type 2 Inflammation – Asthma

    Discover a solution to control mixed eosinophilic and allergic asthma

    What's possible when their child's asthma is under control?

    Consider Dupixent for Asthmatic Patients with High EOS

    Consider Dupixent For asthmatic patients with OCS use

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    Home | go to homepage

    SANOFI, Kingdom of Saudi Arabia, P.O. Box 9874, Jeddah 21423, K.S.A. Tel: +966-12-669-3318,

    Fax: +966-12-663-6191

    For Medical Information, please contact: +966-12-669-3318, ksa.medicalinformation@sanofi.com

    To report any Product Technical Complaints, kindly contact: Email: quality.greatergulf@sanofi.com

    In case of any drug related adverse events, please contact:

    The National Pharmacovigilance Center (NPC):

    Call Center: 19999, E-mail: npc.drug@sfda.gov.sa, Website: https://ade.sfda.gov.sa/

    And Sanofi Pharmacovigilance Department:

    Phone: +966-544-284-797, E-mail: Ksa_pharmacovigilance@sanofi.com

     

    MAT-SA-2100978/V4/NOV 2022

    • Legal notice
    • Cookie policy
    • Privacy policy
    • Sitemap
    • Change country

    YOU WILL NOW BE LEAVING THE SITE

    By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
    Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.

    Continue
    This website is intended exclusively for healthcare professionals residing and/or working in the KSA.
     
    Please choose if you are a healthcare professional and wish to continue on this site or if you are a member of the public to be redirected to the Sanofi website.